Advertisement

ADVERTISEMENT

ASCO

News
Web-Based Pathways Program Reduces Unwarranted Practice Variation
05/28/2020
Deployment of a web-based clinical pathways program resulted in greater uniformity in physician practice at the Dana-Farber Cancer Institute (DFCI), according to a study to be presented at the American Society of...
Deployment of a web-based clinical pathways program resulted in greater uniformity in physician practice at the Dana-Farber Cancer Institute (DFCI), according to a study to be presented at the American Society of...
...
05/28/2020
Journal of Clinical Pathways
News
Practice Patterns, Predictors of Survival for Older Patients With MCL
05/27/2020
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new...
05/27/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up Data Supports Frontline Treatment Option for Older AML Patients
05/21/2020
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
...
05/21/2020
Journal of Clinical Pathways
News
Examining Bone Marrow Biopsies for Response Assessment in Follicular Lymphoma Clinical Trials
05/20/2020
Bone marrow biopsies (BMB) are performed pre/post therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. Sara C Rutherford, MD, Weill Cornell Medicine (New York, NY), and colleagues...
Bone marrow biopsies (BMB) are performed pre/post therapy to confirm complete response (CR) in patients with lymphoma on clinical trials. Sara C Rutherford, MD, Weill Cornell Medicine (New York, NY), and colleagues...
Bone...
05/20/2020
Journal of Clinical Pathways
News
Real-World HRU, Costs in Patients With MCL Treated With Drug Combo vs Chemoimmunotherapy
05/20/2020
Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...
Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...
...
05/20/2020
Journal of Clinical Pathways
News
Integrated Palliative, Oncology Care for AML Improves PROs
05/15/2020
A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...
A study to be presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program (May 29-31, 2020) highlights the results of an integrated palliative and oncology care model for patients...
A...
05/15/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Monotherapies for Relapsed, Refractory Hodgkin Lymphoma
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways
Research in Review
Benefits and Shortcomings of Oncology Value Frameworks for Payers
08/03/2017
JCP Editors
Multiple areas have been identified where oncology value frameworks can be revised in order to increase their utility to payers, according to a study in the Journal of Managed Care & Specialty Pharmacy (June...
Multiple areas have been identified where oncology value frameworks can be revised in order to increase their utility to payers, according to a study in the Journal of Managed Care & Specialty Pharmacy (June...
...
08/03/2017
Journal of Clinical Pathways
Research in Review
ED Visits Prevented Through Improved Cancer Symptom Management and Outpatient Care
06/15/2017
JCP Editors
Better symptom management and readily available outpatient care for patients with cancer can reduce emergency department (ED) visits that do not require admission by as much as 53%, according to a recent...
Better symptom management and readily available outpatient care for patients with cancer can reduce emergency department (ED) visits that do not require admission by as much as 53%, according to a recent...
Better...
06/15/2017
Journal of Clinical Pathways
Research in Review
Recent Breast Cancer HER2 Testing Guideline Update Produces Similar Positivity Rate
06/14/2017
JCP Editors
Updates to the 2013 human epidermal growth factor receptor 2 (HER2) testing guideline in breast cancer did not affect the overall positivity rate or the proportion of patients eligible for targeted therapy, according...
Updates to the 2013 human epidermal growth factor receptor 2 (HER2) testing guideline in breast cancer did not affect the overall positivity rate or the proportion of patients eligible for targeted therapy, according...
...
06/14/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use